Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Veteran Launches Biotech Aiming To Disrupt Eye Drug Market

EyeBio Raises $65m In Series A

Executive Summary

Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.

You may also be interested in...



Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?

There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.

Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?

The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.

Safety Could Differentiate Nkarta’s CAR-NK Cell Therapy

Nkarta has updated its early results for its natural killer cell therapy, where it has shown promising efficacy and potentially superior safety to existing CAR-Ts.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel